Tag Archives: marketing application

New FDA Guidances for May 2015

By Sheila R. Plant, Ph.D., R.A.C., Regulatory Scientist at Cato Research FDA draft and final guidances, released from CDER, CBER, and CDRH in May, are posted. In addition, upcoming advisory committee meetings and other public meetings hosted by FDA are listed … Continue reading

Posted in Cato Research, Clinical Trials, Drug Development, FDA | Tagged , , , , , , , | Comments Off on New FDA Guidances for May 2015

Combination Products: What’s New?

A monoclonal antibody combined with a therapeutic drug. An EpiPen®. A drug packaged with its delivery device. All of these are examples of combination products. A combination product, according to the FDA, is “a product composed of any combination of … Continue reading

Posted in Clinical Trials, FDA, Industry News | Tagged , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

FDASIA, Part 1: The “UFAs”

On 09 July 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA, otherwise known as PDUFA V) was signed into law.  In a 4-part series, we will cover the major changes in FDASIA as follows: Part 1: The … Continue reading

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , , , , , , , , , , , | 4 Comments

Stem Cells: Which Way to the Clinic? (Updated!)

For over two decades, the potential of stem cell therapy to cure some of our most devastating diseases has been touted by the media.  A Google search of “stem cell research” yields over 57 million results, and yet, in mid-2012, … Continue reading

Posted in FDA, Industry News | Tagged , , , , , , , , , , | 3 Comments

New FDA Guidances from April 2012

Here’s a list of the notable guidances released by FDA in April 2012. Continue reading

Posted in FDA, Regulatory Strategy | Tagged , , , , , , | Comments Off on New FDA Guidances from April 2012